| 07/04/25 | 09:30:00 | 7 Apr 2025 | | 2024 Annual Report and Notice of AGM |
| 31/03/25 | 10:30:00 | 31 Mar 2025 | | Extraordinary General Meeting – Poll Results |
| 21/03/25 | 10:00:01 | 21 Mar 2025 | | NMPA Conditional Approval for TAZVERIK® |
| 20/03/25 | 09:30:01 | 20 Mar 2025 | | Retirement of Independent Non-executive Directors |
| 20/03/25 | 07:00:13 | 20 Mar 2025 | | HUTCHMED Highlights Savolitinib SAVANNAH Phase II |
| 19/03/25 | 13:45:00 | 19 Mar 2025 | | Publication of Form 20-F |
| 19/03/25 | 11:00:00 | 19 Mar 2025 | | 2024 Final Results and Business Updates |
| 19/03/25 | 07:00:12 | 19 Mar 2025 | | Phase II/III Study of Fruquintinib and Sintilimab |
| 14/03/25 | 09:30:00 | 14 Mar 2025 | | Adoption of the 2025 Long Term Incentive Plan |
| 14/03/25 | 09:30:00 | 14 Mar 2025 | | Vesting of awards under Long Term Incentive Plan |
| 13/03/25 | 09:30:00 | 13 Mar 2025 | | Notice of Extraordinary General Meeting |
| 06/03/25 | 10:00:00 | 6 Mar 2025 | | Completed Enrollment of Phase II Study |
| 05/03/25 | 10:00:00 | 5 Mar 2025 | | Directorate Change |
| 03/03/25 | 07:00:10 | 3 Mar 2025 | | Overseas Regulatory Announcement |
| 28/02/25 | 15:00:01 | 28 Feb 2025 | | Overseas Regulatory Announcement |
| 19/02/25 | 08:30:01 | 19 Feb 2025 | | Notice of Results |
| 28/01/25 | 09:00:00 | 28 Jan 2025 | | Overseas Regulatory Announcement |
| 14/01/25 | 07:00:07 | 14 Jan 2025 | | Full Approval for ORPATHYS in China |
| 02/01/25 | 07:01:00 | 2 Jan 2025 | | China NDA Acceptance for ORPATHYS and TAGRISSO |
| 02/01/25 | 07:00:07 | 2 Jan 2025 | | Overseas Regulatory Announcement |
| 02/01/25 | 07:00:05 | 2 Jan 2025 | | US$608m Divestment of Non-Core Joint Venture |
| 31/12/24 | 08:30:01 | 31 Dec 2024 | | Appointment of Joint Corporate Broker |
| 30/12/24 | 08:30:00 | 30 Dec 2024 | | Blocklisting Six Monthly Return |
| 13/12/24 | 07:00:07 | 13 Dec 2024 | | HUTCHMED to Receive Milestone Payment from Takeda |
| 12/12/24 | 07:00:08 | 12 Dec 2024 | | Breakthrough Therapy Designation in China |
| 03/12/24 | 10:00:00 | 3 Dec 2024 | | HUTCHMED and Innovent Announce ELUNATE Approval |
| 29/11/24 | 08:30:00 | 29 Nov 2024 | | Total Voting Rights |
| 28/11/24 | 10:32:34 | 28 Nov 2024 | | Continued Inclusion of ORPATHYS in China NRDL |
| 22/11/24 | 07:00:10 | 22 Nov 2024 | | FRUZAQLA® Launched in Japan by Takeda |
| 20/11/24 | 09:30:00 | 20 Nov 2024 | | Appointment of Independent Non-executive Director |
| 06/11/24 | 07:00:08 | 6 Nov 2024 | | Clinical Data to be Presented at ASH and ESMO Asia |
| 31/10/24 | 08:30:01 | 31 Oct 2024 | | First Commercial Milestone Payment |
| 31/10/24 | 08:30:01 | 31 Oct 2024 | | Total Voting Rights |
| 21/10/24 | 09:30:01 | 21 Oct 2024 | | Vesting of awards under the LTIP |
| 16/10/24 | 07:00:06 | 16 Oct 2024 | | SAVANNAH: clinically meaningful response rate |
| 24/09/24 | 08:00:00 | 24 Sept 2024 | | Japan Approval for FRUZAQLA |
| 09/09/24 | 07:00:10 | 9 Sept 2024 | | Clinical Data to be Presented at ESMO and WCLC |
| 30/08/24 | 09:30:00 | 30 Aug 2024 | | Total Voting Rights |
| 30/08/24 | 07:00:14 | 30 Aug 2024 | | Update on Fruquintinib for Gastric Cancer in China |
| 22/08/24 | 09:30:00 | 22 Aug 2024 | | Standard form for notification of major holdings |
| 21/08/24 | 09:30:00 | 21 Aug 2024 | | HUTCHMED to Host Expert Call to discuss ITP |
| 06/08/24 | 10:00:00 | 6 Aug 2024 | | LTIP and Share Option Scheme |
| 31/07/24 | 12:00:00 | 31 Jul 2024 | | 2024 Interim Results and Business Updates |
| 04/07/24 | 07:00:10 | 4 Jul 2024 | | NDA Acceptance in China for Tazemetostat |
| 28/06/24 | 12:35:00 | 28 Jun 2024 | | Overseas Regulatory Announcement: Form F-3 Filing |
| 28/06/24 | 09:30:00 | 28 Jun 2024 | | Blocklisting Six Monthly Return |
| 28/06/24 | 09:30:00 | 28 Jun 2024 | | Total Voting Rights |
| 26/06/24 | 09:30:00 | 26 Jun 2024 | | HUTCHMED to Announce 2024 HY Financial Results |
| 24/06/24 | 10:30:00 | 24 Jun 2024 | | Save the Date: HUTCHMED to Present R&D Updates |
| 24/06/24 | 07:00:03 | 24 Jun 2024 | | European Commission Approval for FRUZAQLA |
